BCL2 and B-cell chronic lymphocytic leukemia: Recently, medium-sized compounds such as the antitumor agent eribulin (molecular weight = 729.9)43 and the BCL-2 inhibitor venetoclax (molecular weight = 868.4) for chronic lymphocytic leukaemia with 17p deletion44 have been approved.